Literature DB >> 3094197

Nonenzymatic oxygen activation and stimulation of lipid peroxidation by doxorubicin-copper.

K B Wallace.   

Abstract

Addition of cupric sulfate to neutral solutions of doxorubicin resulted in spectrophotometric, fluorometric, and chromatographic changes indicative of a direct chemical interaction. Associated with these changes was a copper-dependent consumption of dissolved oxygen and a superoxide dismutase-sensitive reduction of ferricytochrome c, suggesting the liberation of superoxide free radicals. Addition of equimolar ethylenediaminetetraacetic acid (EDTA) completely inhibited, but did not reverse, the effect of copper on the spectrophotometric, fluorometric, and chromatographic properties of the drug. EDTA also abolished the copper-stimulated consumption of oxygen and reduction of ferricytochrome regardless of the time of addition. Oxygen-free radical formation by the drug-copper complex was further implicated by the stimulation of lipid peroxidation, which was completely inhibited by adding EDTA. Inhibition by superoxide dismutase, catalase, and dimethyl urea implicates the involvement of assorted oxygen-free radicals in doxorubicin-copper stimulated lipid peroxidation. The data demonstrate that despite the implication of hydrogen peroxide and hydroxyl radicals in doxorubicin-copper stimulated lipid peroxidation, the immediate product of dioxygen reduction by the complex is superoxide-free radicals. The suggested occurrence of doxorubicin-copper complexes in vivo infers that nonenzymatic generation of oxygen-free radicals by the chelate may contribute to the mechanism of toxicity of doxorubicin and related anthraquinone anticancer agents observed clinically.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094197     DOI: 10.1016/0041-008x(86)90400-x

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

1.  Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity.

Authors:  Azadeh Kheirolomoom; Lisa M Mahakian; Chun-Yen Lai; Heather A Lindfors; Jai Woong Seo; Eric E Paoli; Katherine D Watson; Eric M Haynam; Elizabeth S Ingham; Li Xing; R Holland Cheng; Alexander D Borowsky; Robert D Cardiff; Katherine W Ferrara
Journal:  Mol Pharm       Date:  2010-12-06       Impact factor: 4.939

2.  DNA damage induced by doxorubicin, 4'-epidoxorubicin and their copper(II) complexes.

Authors:  D Cova; M Sassano; E Monti; F Piccinini
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

3.  Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia.

Authors:  Azadeh Kheirolomoom; Chun-Yen Lai; Sarah M Tam; Lisa M Mahakian; Elizabeth S Ingham; Katherine D Watson; Katherine W Ferrara
Journal:  J Control Release       Date:  2013-08-28       Impact factor: 9.776

4.  Cardiotoxicity and antitumor activity of a copper(II)-doxorubicin chelate.

Authors:  E Monti; L Paracchini; F Piccinini; V Malatesta; F Morazzoni; R Supino
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.

Authors:  B C Hüsken; J de Jong; B Beekman; R C Onderwater; W J van der Vijgh; A Bast
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Tumor-specific activatable biopolymer nanoparticles stabilized by hydroxyethyl starch prodrug for self-amplified cooperative cancer therapy.

Authors:  Yuxuan Xiong; Zibing Wang; Qiang Wang; Qingyuan Deng; Jitang Chen; Jianshuang Wei; Xiaoquan Yang; Xiangliang Yang; Zifu Li
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.